|
🐜
|
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
22 auth.
S. Castaigne,
C. Pautas,
C. Terré,
E. Raffoux,
D. Bordessoule,
J. Bastie,
O. Legrand,
X. Thomas,
P. Turlure,
O. Reman,
...
T. Revel,
L. Gastaud,
Noémie de Gunzburg,
N. Contentin,
Estelle Henry,
J. Marolleau,
Ahmad Aljijakli,
P. Rousselot,
P. Fenaux,
C. Preudhomme,
S. Chevret,
H. Dombret
|
9 |
2012 |
9
🐜
|
|
🐜
|
Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.
20 auth.
X. Thomas,
J. Boiron,
F. Huguet,
H. Dombret,
K. Bradstock,
N. Vey,
T. Kovacsovics,
A. Delannoy,
N. Fegueux,
P. Fenaux,
...
A. Stamatoullas,
J. Vernant,
O. Tournilhac,
A. Buzyn,
O. Reman,
C. Charrin,
C. Boucheix,
J. Gabert,
V. Lheritier,
D. Fiére
|
9 |
2004 |
9
🐜
|
|
🐜
|
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
26 auth.
M. André,
T. Girinsky,
M. Federico,
O. Reman,
C. Fortpied,
M. Gotti,
O. Casasnovas,
P. Brice,
R. W. van der Maazen,
A. Re,
V. Edeline,
C. Fermé,
G. V. van Imhoff,
F. Merli,
R. Bouabdallah,
...
C. Sebban,
L. Specht,
A. Stamatoullas,
R. Delarue,
V. Fiaccadori,
M. Bellei,
T. Raveloarivahy,
A. Versari,
M. Hutchings,
M. Meignan,
J. Raemaekers
|
8 |
2017 |
8
🐜
|
|
🐜
|
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
35 auth.
C. Fermé,
H. Eghbali,
J. Meerwaldt,
C. Rieux,
J. Bosq,
F. Berger,
T. Girinsky,
P. Brice,
M. V. van't Veer,
J. Walewski,
P. Lederlin,
U. Tirelli,
P. Carde,
E. Van Den Neste,
E. Gyan,
...
M. Monconduit,
M. Diviné,
J. Raemaekers,
G. Salles,
E. Noordijk,
G. Creemers,
J. Gabarre,
A. Hagenbeek,
O. Reman,
M. Blanc,
J. Thomas,
B. Vié,
J. Kluin-Nelemans,
F. Viseu,
J. Baars,
P. Poortmans,
P. Lugtenburg,
C. Carrie,
J. Jaubert,
M. Henry-Amar
|
8 |
2007 |
8
🐜
|
|
🐜
|
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
20 auth.
A. de Labarthe,
P. Rousselot,
F. Huguet-Rigal,
É. Delabesse,
Francis Witz,
S. Maury,
Delphine Réa,
J. Cayuela,
M. Vekemans,
O. Reman,
...
A. Buzyn,
Arnaud Pigneux,
M. Escoffre,
Yves Chalandon,
Elizabeth Macintyre,
V. Lheritier,
J. Vernant,
Xavier Thomas,
N. Ifrah,
Hervé Dombret
|
8 |
2007 |
8
🐜
|
|
🐜
|
Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.
20 auth.
S. Botton,
H. Dombret,
M. Sanz,
J. Miguel,
D. Caillot,
R. Zittoun,
M. Gardembas,
A. Stamatoulas,
E. Conde,
A. Guerci,
...
C. Gardin,
K. Geiser,
D. Makhoul,
O. Reman,
J. Serna,
F. Lefrère,
C. Chomienne,
C. Chastang,
L. Degos,
P. Fenaux
|
8 |
1998 |
8
🐜
|
|
🐜
|
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.
25 auth.
K. Beldjord,
S. Chevret,
V. Asnafi,
F. Huguet,
M. Boulland,
T. Leguay,
X. Thomas,
J. Cayuela,
N. Grardel,
Y. Chalandon,
N. Boissel,
B. Schaefer,
É. Delabesse,
H. Cavé,
P. Chevallier,
...
A. Buzyn,
T. Fest,
O. Reman,
J. Vernant,
V. Lheritier,
M. Béné,
M. Lafage,
E. Macintyre,
N. Ifrah,
H. Dombret
|
8 |
2014 |
8
🐜
|
|
🐜
|
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group
18 auth.
A. Taksin,
O. Legrand,
E. Raffoux,
T. Revel,
X. Thomas,
N. Contentin,
R. Bouabdallah,
C. Pautas,
P. Turlure,
O. Reman,
...
C. Gardin,
B. Varet,
S. Botton,
F. Pousset,
H. Farhat,
S. Chevret,
H. Dombret,
S. Castaigne
|
8 |
2007 |
8
🐜
|
|
🐜
|
Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.
22 auth.
N. Dhédin,
A. Huynh,
S. Maury,
R. Tabrizi,
K. Beldjord,
V. Asnafi,
X. Thomas,
P. Chevallier,
S. Nguyen,
V. Coiteux,
...
J. Bourhis,
Y. Hichri,
M. Escoffre-barbe,
O. Reman,
C. Graux,
Y. Chalandon,
D. Blaise,
U. Schanz,
V. Lheritier,
J. Cahn,
H. Dombret,
N. Ifrah
|
7 |
2015 |
7
🐜
|
|
🐜
|
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.
36 auth.
P. Rousselot,
M. Coudé,
N. Gokbuget,
C. Gambacorti Passerini,
S. Hayette,
J. Cayuela,
F. Huguet,
T. Leguay,
P. Chevallier,
C. Salanoubat,
C. Bonmati,
M. Alexis,
M. Hunault,
S. Glaisner,
P. Agapé,
...
C. Berthou,
E. Jourdan,
J. Fernandes,
L. Sutton,
A. Banos,
O. Reman,
B. Lioure,
X. Thomas,
N. Ifrah,
M. Lafage-Pochitaloff,
A. Bornand,
Laure Morisset,
V. Robin,
H. Pfeifer,
A. Delannoy,
J. Ribera,
R. Bassan,
M. Delord,
D. Hoelzer,
H. Dombret,
O. Ottmann
|
7 |
2016 |
7
🐜
|
|
🐜
|
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial
20 auth.
E. Tavernier,
J. Boiron,
F. Huguet,
K. Bradstock,
N. Vey,
T. Kovacsovics,
A. Delannoy,
N. Fegueux,
P. Fenaux,
A. Stamatoullas,
...
O. Tournilhac,
A. Buzyn,
O. Reman,
C. Charrin,
C. Boucheix,
J. Gabert,
V. Lheritier,
J. Vernant,
H. Dombret,
X. Thomas
|
7 |
2007 |
7
🐜
|
|
🐜
|
NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.
20 auth.
V. Asnafi,
A. Buzyn,
Sandrine Le Noir,
F. Baleydier,
A. Simon,
K. Beldjord,
O. Reman,
F. Witz,
T. Fagot,
E. Tavernier,
...
P. Turlure,
T. Leguay,
F. Huguet,
J. Vernant,
Francis Daniel,
M. Béné,
N. Ifrah,
X. Thomas,
H. Dombret,
E. Macintyre
|
7 |
2009 |
7
🐜
|
